

LEARNER OUTCOMES

PROVIDING COMPREHENSIVE CANCER CARE WITH ALOHA IN AN ISLAND STATE October 16, 17, 18, 2020

GENERAL CONFERENCE OUTCOMES

- Make appropriate referrals to community resources for patients who experience barriers in obtaining cancer care.
- Identify and discuss disparities in cancer outcomes based on geographical issues particular to Hawaii.
- Apply knowledge gained of recently approved immunotherapy agents for cancer care.
- Provide example for the multidisciplinary cancer care team, of the unique cancer care disparities for the individual islands that encompass the state of Hawai'i.

SESSION OUTCOMES

Geographic Disparities in Cancer in Hawaii

Brenda Hernandez, PhD, MPH

- Describe geographic disparities in cancer across the state of Hawaii and compared to the U.S. overall
- Describe other disparities in cancer within Hawaii's population

Managing Complexities of Cancer Care with Geographic Challenges

Panel

- To describe the role of navigation in supporting cancer patients through their cancer journey.
- To understand the unique challenges of the islands of Kauai, Maui, and Hawaii and the impact on cancer care

Emerging Therapies and Access Issues in Hawaii/ Phase I Clinical Trials

Diana Martin, MS, RN, CCRP/Randall Holcombe, MD, MBA

- Understand the indications for and impact of early phase clinical trials
- Understanding the role of research nursing for phase I trials
- Recognize the components of phase I trials that are unique and distinct from standard oncology nursing practice.

CAR-T Cell Therapy

Stephanie Si Lim, MD

- Demonstrate an understanding of the therapeutic benefits of CAR T cell therapy for patients with difficult to treat cancers
- Recognize the common CAR T associated toxicities, and appreciate the need for continued scientific research to optimize this new therapy

Rapid Development of Immunotherapy in Cancer Care

Rowena Schwartz, PharmD

- Describe the rationale for immunotherapy(s) in the treatment of cancer, with a focus on the immune checkpoint inhibitors (ICI).
- Outline strategies to prevent, monitor and manage toxicities associated with ICI in cancer treatment.
 - Immune-related adverse effects (irAE)
 - Toxicities beyond irAE
 - Patient and caregiver education regarding irAE
- Discuss strategies that are being evaluated to improve efficacy and toxicities of immunotherapy(s) in cancer treatment.

Supporting Patients on Oral Anticancer Therapies

Lisa Barbarotta, MS, ANP-BC, AOCNS

- Discuss the impact of poor adherence on cancer outcomes including survival
- Identify 5 barriers to adherence to oral anticancer therapies and describe strategies to mitigate risk.
- Describe effective strategies to provide patient education that promotes adherence.
- Describe methods for monitoring adherence to oral anticancer therapies